Dose Timing of an Angiotensin II Receptor Blocker/Calcium Channel Blocker Combination in Hypertensive Patients With Paroxysmal Atrial Fibrillation

Journal of Clinical Hypertension

Volumn 18, Issue 10, 2016, Pages 1036-1044

  Kario, Kazuomi ^a   Hoshide, Satoshi ^a   Uchiyama, Kazuaki ^b   Yoshida, Tetsuro ^c   Okazaki, Osamu ^d   Noshiro, Takao ^e   Aoki, Hirotaka ^f   Mizuno, Hiroyuki ^a   Matsumoto, Yuri ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Uchiyama Clinic   (Japan)

^c Onga Nakama Medical Association Onga Hospital   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e Noshiro Clinic   (Japan)

^f Koga Red Cross Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMLODIPINE; AMLODIPINE PLUS TELMISARTAN; CALCIUM CHANNEL BLOCKING AGENT; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; DRUG COMBINATION; TELMISARTAN AMLODIPINE COMBINATION;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BEDTIME DOSAGE; BLOOD PRESSURE MONITOR; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG WITHDRAWAL; HOME MONITORING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NIGHT; OPEN STUDY; PAROXYSMAL ATRIAL FIBRILLATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WAKEFULNESS; ATRIAL FIBRILLATION; BLOOD PRESSURE; CIRCADIAN RHYTHM; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; FEMALE; MALE; METABOLISM; TREATMENT OUTCOME;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CIRCADIAN RHYTHM; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; MALE; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84961279295     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12814     Document Type: Article

References (40)

1. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840–844.
2. Thomas MC, Dublin S, Kaplan RC, et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens. 2008;21:1111–1116.
3. Camm AJ, Savelieva I, Bharati S, et al. Atrial tachycardia, flutter, and fibrillation. In: Saksena S, Camm AJ, eds. Electrophysiological Disorders of the Heart. London: Elsevier Churchill-Livingstone; 2005:283–363.
4. Kokubo Y, Watanabe M, Higashiyama A, et al. Interaction of blood pressure and body mass index with risk of incident atrial fibrillation in a Japanese urban cohort: The Suita study. Am J Hypertens. 2015;28:1355–1361.
5. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–2219.
6. Lévy S. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation-indications and contraindications. Nat Clin Pract Cardiovasc Med. 2006;3:220–225.
7. Patlolla V, Alsheikh-Ali AA, Al-Ahmad AM. The renin-angiotensin system: a therapeutic target in atrial fibrillation. Pacing Clin Electrophysiol. 2006;29:1006–1012.
8. Makkar KM, Sanoski CA, Spinler SA. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy. 2009;29:31–48.
9. Schneider MP, Hua TA, Böhm M, et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299–2307.
10. ACTIVE I Investigators, Yusuf S, Healey JS, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364:928–938.
11. GISSI-AF Investigators, Disertori M, Latini R, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606–1617.
12. Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace. 2011;13:473–479.
13. Patton KK, Heckbert SR, Alonso A, et al. N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. Heart. 2013;99:1832–1836.
14. Mabuchi N, Tsutamoto T, Maeda K, et al. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J. 2000;64:765–771.
15. de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55:725–731.
16. Giantin V, Perissinotto E, Franchin A, et al. Ambulatory blood pressure monitoring in elderly patients with chronic atrial fibrillation: is it absolutely contraindicated or a useful tool in clinical practice and research? Hypertens Res. 2013;36:889–894.
17. Lip GY, Zarifis J, Beevers M, et al. Ambulatory blood pressure monitoring in atrial fibrillation. Am J Cardiol. 1996;78:350–353.
18. The Japanese Society of Hypertension. Guidelines for the Management of Hypertension 2014. Tokyo: Life Science Publishing Co., Ltd.; 2014.
19. Hermida RC, Ayala DE, Fernández JR, et al. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension. 2007;50:715–722.
20. Kario K, Hoshide S, Shimizu M, et al. Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J Hypertens. 2010;28:1574–1583.
21. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107:1401–1406.
22. Matsui Y, O'Rourke MF, Hoshide S, et al. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension. 2012;59:1132–1138.
23. Matsui Y, Ishikawa J, Eguchi K, et al. Maximum value of home blood pressure: a novel indicator of target organ damage in hypertension. Hypertension. 2011;57:1087–1093.
24. Metoki H, Ohkubo T, Kikuya M, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension. 2006;47:149–154.
25. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension. 2010;56:765–773.
26. Kario K, Matsuo T, Kobayashi H, et al. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension. 1996;27:130–135.
27. Kario K, Pickering TG, Matsuo T, et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001;38:852–857.
28. Hoshide S, Kario K, Hoshide Y, et al. Associations between nondipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens. 2003;16:434–438.
29. Nagai M, Hoshide S, Ishikawa J, et al. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. J Hypertens. 2008;26:1636–1641.
30. Yano Y, Inokuchi T, Hoshide S, et al. Association of poor physical function and cognitive dysfunction with high nocturnal blood pressure level in treated elderly hypertensive patients. Am J Hypertens. 2011;24:285–291.
31. Hoshide S, Ishikawa J, Eguchi K, et al. Masked nocturnal hypertension and target organ damage in hypertensives with well-controlled self-measured home blood pressure. Hypertens Res. 2007;30:143–149.
32. Parati G, Dolan E, Ley L, et al. Impact of antihypertensive combination and monotreatments on blood pressure variability: assessment by old and new indices. Data from a large ambulatory blood pressure monitoring database. J Hypertens. 2014;32:1326–1333.
33. Palatini P, Reboldi G, Beilin LJ, et al. Added predictive value of night-time blood pressure variability for cardiovascular events and mortality: the Ambulatory Blood Pressure-International Study. Hypertension. 2014;64:487–493.
34. Shimizu M, Ishikawa J, Yano Y, et al. Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J Hypertens. 2012;30:1015–1021.
35. Hoshide S, Fukutomi M, Eguchi K, et al. Change in high-sensitive cardiac troponin T on hypertensive treatment. Clin Exp Hypertens. 2013;35:40–44.
36. Kawasaki T, Cugini P, Uezono K, et al. Circadian variations of total renin, active renin, plasma renin activity and plasma aldosterone in clinically healthy young subjects. Horm Metab Res. 1990;22:636–639.
37. Naito Y, Tsujino T, Fujioka Y, et al. Augmented diurnal variations of the cardiac renin-angiotensin system in hypertensive rats. Hypertension. 2002;40:827–833.
38. Kala R, Fyhrquist F, Eisalo A. Diurnal variation of plasma angiotensin II in man. Scand J Clin Lab Invest. 1973;31:363–365.
39. Kawasaki T, Ueno M, Uezono K, et al. Differences and similarities among circadian characteristics of plasma renin activity in healthy young women in Japan and the United States. Am J Med. 1980;68:91–96.
40. Brandenberger G, Follenius M, Goichot B, et al. Twenty-four-hour profiles of plasma renin activity in relation to the sleep-wake cycle. J Hypertens. 1994;12:277–283.